Generic name: delafloxacin meglumine 450mg
Dosage form: tablet
Medically reviewed on June 30, 2017.
Important Administration Instructions
Administer BAXDELA at least 2 hours before or 6 hours after antacids containing magnesium, or aluminum, with sucralfate, with metal cations such as iron, or with multivitamin preparations containing zinc or iron, or with didanosine buffered tablets for oral suspension or the pediatric powder for oral solution [see Drug Interactions (7.1)].
BAXDELA Tablets can be taken with or without food [see Clinical Pharmacology 12.3)].
If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.
BAXDELA for Injection
Do NOT administer BAXDELA for Injection with any solution containing multivalent cations, e.g., calcium and magnesium, through the same intravenous line [see Drug Interactions (7.1)]. Do NOT Co-infuse BAXDELA for Injection with other medications [see Dosage and Administration (2.4)].
Recommended Dosage Regimen
For treatment of adults with ABSSSI, the recommended dosage regimen of BAXDELA is as follows:
- Administer 300 mg of BAXDELA for Injection every 12 hours over 60 minutes by intravenous infusion for 5 to 14 days or,
- Administer 300 mg of BAXDELA for Injection every 12 hours over 60 minutes by intravenous infusion, then switch to a 450 mg BAXDELA tablet orally every 12 hours at the discretion of the physician for a total duration of 5 to 14 days or,
- Administer a 450 mg BAXDELA tablet orally every 12 hours for a total duration of 5 to 14 days.
Dosage in Patients with Renal Impairment
Table 1 below describes the dosage modification based on the estimated glomerular filtration rate (eGFR) that is recommended in patients with renal impairment. Dosage adjustment is required for patients with severe renal impairment (eGFR 15-29 mL/min/1.73m2).
In patients with severe renal impairment receiving BAXDELA intravenously, closely monitor serum creatinine levels and eGFR [see Use in Specific Populations (8.7)]. If serum creatinine level increases, consider switching to BAXDELA Tablets. Discontinue BAXDELA if eGFR decreases to <15 mL/min/1.73 m2.
|Estimated Glomerular Filtration Rate (eGFR)
|Recommended Dosage Regimen†|
|BAXDELA Tablets||BAXDELA for Injection‡|
|30-89||No dosage adjustment||No dosage adjustment|
|15-29||No dosage adjustment||200 mg every 12 hours
200 mg every 12 hours, then switch to a 450 mg BAXDELA tablet orally every 12 hours at the discretion of the physician
|End Stage Renal Disease (ESRD) (<15), including patients on hemodialysis (HD)||Not Recommended§|
Preparation and Administration of BAXDELA for Injection Intravenous Solution
Reconstitution and Dilution
- BAXDELA must be reconstituted and then further diluted under aseptic conditions. Reconstitute the powder in the BAXDELA vial using 10.5 mL of 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection for each 300 mg vial. Shake the vial vigorously until contents are completely dissolved. The reconstituted vial contains 300 mg per 12 mL (25 mg/mL) of BAXDELA as a clear yellow to amber colored solution.
- The reconstituted solution must then be diluted to a total volume of 250 mL using either 0.9% Sodium Chloride or D5W to achieve a concentration of 1.2 mg/mL, prior to administration. Prepare the required dose for intravenous infusion by withdrawing the appropriate volume from the reconstituted vial per Table 2 below:
|BAXDELA for Injection Dose||Volume of Reconstituted Solution to Withdraw|
|300 mg||12 mL|
|200 mg||8 mL|
- Aseptically transfer the required volume of BAXDELA reconstituted solution from the vial to an intravenous bag to achieve a 250 mL volume of infusion solution. Discard any unused portion of the reconstituted solution.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Storage of the Reconstituted and Diluted Solutions
Reconstituted vials, as described above, may be stored either refrigerated at 2°C to 8°C (36°F to 46°F), or at controlled room temperature 20°C to 25°C (68°F to 77°F) for up to 24 hours. Do not freeze.
Once diluted into the intravenous bag, as described above, BAXDELA may be stored either refrigerated at 2°C to 8°C (36°F to 46°F) or at a controlled room temperature of 20°C to 25°C (68°F to 77°F) for up to 24 hours. Do not freeze.
After reconstitution and dilution, administer BAXDELA by intravenous infusion, using a total infusion time of 60 minutes [see Dosage and Administration (2.1)].
The compatibility of reconstituted BAXDELA with intravenous medications, additives, or substances other than D5W or 0.9% Sodium Chloride Injection has not been established. If a common intravenous line is being used to administer other drugs in addition to BAXDELA the line should be flushed before and after each BAXDELA infusion with 0.9% Sodium Chloride Injection or D5W.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Baxdela (delafloxacin)
- Baxdela Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: quinolones
- Baxdela oral/injection
- Baxdela (Delafloxacin Injection)
- Baxdela (Delafloxacin Tablets)
- Baxdela (Advanced Reading)
- Baxdela Intravenous (Advanced Reading)